CNDO103 is Apogossypol, a rationally designed derivative of Gossypol. Apogossypol targets the Bcl-2 family pro-survival proteins class -- inhibiting five of the six members of the Bcl-2 family. In preclinical studies, oral Apogossypol appears to have improved physiologic and pharmaceutical properties compared to other drugs in the same class. Apogossypol shows activity against both hematologic and epithelial tumors.
The Bcl-2 family of proteins control naturally occurring, programmed cell death called apoptosis. In cancer, increased levels of the Bcl-2 pro-survival proteins lead to abnormal apoptosis, uncontrolled cell growth and the development of resistance to standard therapies. The inhibition of Bcl-2 pro-survival proteins may normalize apoptosis, cause tumor shrinkage and make resistant tumors sensitive to standard treatments.
Burnham Institute for Medical Research
Burnham Institute for Medical Research conducts world-class
collaborative research dedicated to finding cures for human disease,
improving quality of life, and thus creating a legacy for its employees,
donors, and community. The Institute is headquartered in La Jolla, Calif.,
where it was established as a nonprofit, public benefit corporation in 1976
and is now home to four centers: a National Cancer Institute-designated
Cancer Center; the Del E. Webb Center for Neurosciences, Aging and Stem
Cell Research; the Infectious and Inflammatory Disease Center and the
Sanford Children's Health Research Center. In 2006, Burnham established a
center for bionanotechnology research at the University of California,
Santa Barbara. Burnham is currently establishing a campus at Lake Nona in
Orlando, Florida that will focus on diabetes and obesity research and will
expand the Institute's drug discovery capabilities. Today, Burnham employs
more than 820 people and ranks consistently among the world's top 25
|SOURCE Coronado Biosciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved